3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Cholangiocarcinoma
6
Gastrointestinal Neoplasms
3
Carcinoma, Transitional Cell
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
1
Digestive System Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Advanced Non Small Cell Lung Cancer
1
Interventions
Cyclophosphamide
72
fludarabine
65
Tacrolimus
43
fludarabine phosphate
40
Whole-Body Irradiation
37
Mycophenolic Acid
35
Busulfan
32
Melphalan
28
Antilymphocyte Serum
23
thymoglobulin
22
Thiotepa
20
Methotrexate
20
Standard of Care
19
Stem Cell Transplantation
17
Practice Guidelines as Topic
17
Granulocyte Colony-Stimulating Factor
17
Rituximab
15
Surveys and Questionnaires
12
Sirolimus
12
Filgrastim
12
Interviews as Topic
11
Cyclosporine
11
Blood Specimen Collection
11
Peripheral Blood Stem Cell Transplantation
10
Exercise
10
venetoclax
9
Mesna
9
Cytarabine
9
Bortezomib
9
Hematopoietic Stem Cell Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hematologic Neoplasms
×
pemigatinib
×
Clear all
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled